Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT00457587
Active, not recruiting Observational

Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma

NCT00457587 · tracked via the Priya Life Science Germany tracker
Sponsor
University of Wuerzburg
Phase
Observational
Started
2005-09
Last updated
2026-05-07

Condition(s) studied

Adrenocortical CarcinomaCushing's Syndrome

Study summary

Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. Surgical resection of the tumor is the treatment of choice. However, even after complete resection more than 80 % of patients will experience recurrence of disease. Therefore, new treatment options are urgently needed. This pre-clinical study try to lay the foundations for a successful immunotherapy in patients with ACC.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * patients with histological proven adrenocortical carcinoma * healthy persons as control group * Life expectancy \> 6 months Exclusion Criteria: * autoimmune diseases * severe clinical condition

Primary outcome measure(s)

  • To find reasonable antigens for a vaccination therapy in ACC — day of blood sampling
  • To investigate the role of tumor-induced suppression in ACC — NA, in vitro study

Trial sites (1)

FacilityCityRegionStatus
Dept. of Medicine I, University of Wuerzburg Würzburg Germany

More University of Wuerzburg trials in Germany

Registry for Hypoparathyroidism Wuerzburg Recruiting
Adrenal Tumors - Pathogenesis and Therapy Recruiting
Effects of Isolated Lumbar Extension Resistance Training Alone and in Combination with General Exercise and Manual Therapy Active, not recruiting
German Adrenocortical Carcinoma Registry Recruiting
I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer Active, not recruiting

Other trials for the same condition

Adrenal Tumors - Pathogenesis and Therapy Recruiting
German Adrenocortical Carcinoma Registry Recruiting
Evaluation of Side Effects of Mitotane Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00457587 on ClinicalTrials.gov ↗ ← All trials in Germany